SLC7A5 and prostate carcinoma: Studies indicate that SLC7A5 shows significantly elevated expression in various malignant tumors, including GC, colon cancer, lung cancer, and prostate cancer (Wang et al. 2016; Najumudeen et al. 2021), especially has been shown to be a promoter of GC (Wang et al. 2013).